Iovance: Buy Now Before Many Growth Catalysts Kick In Iovance raised 2026 revenue guidance to $410–...

Iovance: Buy Now Before Many Growth Catalysts Kick In Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing losses. I project gross margins reaching 65–70%, although continued cash burn and potential dilution remain risks.